CompanyGraph
Hainan Shuangcheng Pharmaceuticals Co. Ltd.
002693 · SZSE · China
shuangchengmed.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 5.7: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.14BCNY614.67M · vs all stocks (USD)
Trailing P/E
128.13xRevenue (TTM)
288.53MCNY42.85M · vs all stocks (USD)
Profit Margin
11.27%Beta
0.4840xvs all stocks
52-Week Change
20.24%vs all stocks
Market Capitalization
4.14BCNY614.67M · vs all stocks (USD)
Enterprise Value
4.09BCNY607.33M · vs all stocks (USD)
Trailing P/E
128.13xPrice to Sales (TTM)
14.73xPrice to Book (MRQ)
10.22xEnterprise to Revenue
14.17xEnterprise to EBITDA
48.44xGross Margin
62.35%Profit Margin
11.27%Operating Margin
6.92%Return on Assets (TTM)
2.54%Return on Equity (TTM)
5.33%Revenue (TTM)
288.53MCNY42.85M · vs all stocks (USD)
Revenue per Share (TTM)
0.7570CNYUpdated Aug 20, 2026Quarterly Revenue Growth
32.10%Gross Profit (TTM)
156.23MCNY23.20M · vs all stocks (USD)
EBITDA (TTM)
76.11MCNY11.30M · vs all stocks (USD)
Net Income (TTM)
32.53MCNY4.83M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
2.53%Operating Cash Flow (TTM)
85.98MCNY12.77M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
24.01MCNY3.57M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
8.07MCNYFY2025 · Dec 31, 2025Revenue
276.76MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
125.24MCNYFY2025 · Dec 31, 2025Gross Profit
151.53MCNYFY2025 · Dec 31, 2025Operating Income
24.06MCNY3.57M · vs all stocks (USD)
Pre-tax Income
8.16MCNYFY2025 · Dec 31, 2025Income Tax Expense
-764.41KCNYFY2025 · Dec 31, 2025Net Income
8.92MCNYFY2025 · Dec 31, 2025EBIT
17.80MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
76.11MCNYFY2025 · Dec 31, 2025Research & Development
8.09MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
46.39MCNYFY2025 · Dec 31, 2025Other Operating Expenses
13.01MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
156.37KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
9.65MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0500CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
380.86MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
380.86MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
8.92MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.12MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-18.97MCNYFY2025 · Dec 31, 2025Free Cash Flow
-61.18MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
59.05MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
8.92MCNYFY2025 · Dec 31, 2025Other Non-cash Items
11.96MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-51.02MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
11.17MCNYFY2025 · Dec 31, 2025Capital Expenditures
-42.21MCNYFY2025 · Dec 31, 2025Purchase of Investments
-199.60MCNYFY2025 · Dec 31, 2025Sale of Investments
199.88MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-41.93MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
29.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-28.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-7.27MCNYFY2025 · Dec 31, 2025Other Financing Charges
1.15MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-5.12MCNYFY2025 · Dec 31, 2025Shares Outstanding
414.69MSharesUpdated Aug 20, 2026Float Shares
411.90MSharesUpdated Aug 20, 2026% Held by Insiders
53.42%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
74.14MCNY11.01M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1790CNYUpdated Aug 20, 2026Total Debt (MRQ)
294.43MCNY43.73M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.7012xCurrent Ratio (MRQ)
0.6580xBook Value per Share (MRQ)
1.00CNYUpdated Aug 20, 2026Total Assets
825.78MCNY122.64M · vs all stocks (USD)
Total Current Assets
204.71MCNYFY2025 · Dec 31, 2025Total Liabilities
405.25MCNYFY2025 · Dec 31, 2025Total Non-current Assets
621.06MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
98.41MCNYFY2025 · Dec 31, 2025Total Current Liabilities
306.83MCNYFY2025 · Dec 31, 2025Cash
59.05MCNYFY2025 · Dec 31, 2025Cash Equivalents
34.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
59.05MCNYFY2025 · Dec 31, 2025Other Short-term Investments
46.43KCNYFY2025 · Dec 31, 2025Accounts Receivable
62.21MCNYFY2025 · Dec 31, 2025Inventory
66.09MCNYFY2025 · Dec 31, 2025Accounts Payable
23.84MCNYFY2025 · Dec 31, 2025Short-term Debt
124.72MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.85MCNYFY2025 · Dec 31, 2025Long-term Debt
89.00MCNYFY2025 · Dec 31, 2025Common Stock (Book)
414.69MCNYFY2025 · Dec 31, 2025Retained Earnings
-406.22MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
420.53MCNY62.46M · vs all stocks (USD)
52-Week Low
6.36CNYUpdated Aug 20, 202652-Week High
12.43CNYUpdated Aug 20, 202652-Week Change
20.24%vs all stocks
Beta
0.4840xvs all stocks
50-Day MA
9.34CNYUpdated Aug 20, 2026200-Day MA
8.40CNYUpdated Aug 20, 2026Avg 10-Day Volume
26.41MSharesUpdated Aug 20, 2026Avg 30-Day Volume
28.09MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.0800CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.7: safe zoneNotable
Altman Z-Score: 5.70
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Tectonic Therapeutic Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Allogene Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Scitop Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TTY Biopharm Company Limited
Tier 1ProductionApproval-Gated PipelineRule
Kexing Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hangzhou AGS Medtech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Seers Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule